GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers

Alzheimer's Disease Clinical Trial

Official title:

Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of GSK2647544 and Its Potential Pharmacokinetic Interaction With Simvastatin in Healthy Volunteers

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01978327
• Other study ID #: 200592
• Status: Terminated
• Phase: Phase 1
• First received: October 31, 2013
• Last updated: June 7, 2017
• Start date: November 22, 2013
• Est. completion date: March 3, 2014

Study information

• Verified date: June 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

GSK2647544 is an orally available, selective inhibitor of Lp PLA2 that is being developed for the treatment of Alzheimer's disease. The current study is a single-blind, randomised, placebo-controlled, 4-cohort study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat doses of GSK2647544. Cohorts 1, 2 and 3 will evaluate escalating doses of GSK2647544 in young healthy volunteers for 7 days, 7 days, and 14 days, respectively. Cohort 4 will evaluate repeat doses of GSK2647544 in healthy elderly volunteers for 14 days. Additionally, Cohorts 1 and 3 will include an assessment of potential drug-drug interaction with simvastatin to examine CYP3A4 inhibition by GSK2647544.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: March 3, 2014
• Est. primary completion date: March 3, 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Males and females who are 18 to 64 years of age inclusive, defined as young subjects in this study, are eligible for Cohorts 1-3 only

• Males and females who are =65 years of age, defined as elderly subjects in this study, are eligible for Cohort 4 only

• Healthy as determined by a responsible and experienced physician

• A female subject is eligible to participate if she is of non-childbearing potential

• Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods

• Body weight > 50 kg (110 pounds) and body mass index (BMI) between 19 and 32

• Aspartate aminotransferase (AST), Alanine transaminase (ALT), alkaline phosphatase and bilirubin <= 1.5xUpper Limit of Normal (ULN)

• Average of triplicate QTcB values and average of triplicate QTcF values must both < 450 msec

• Capable of giving written informed consent

Exclusion Criteria:

• Subjects with Lp-PLA2 activity <=20 nanomole/minute/milliliter (mL)(for subjects with 2 known birth parents of at least 50% Japanese, Chinese, or Korean ancestry)

• History of asthma, anaphylaxis or anaphalactoid reactions, severe allergic responses

• History of hypercoagulable state or history of thrombosis

• History of biliary tract disease including a history of liver disease with elevated liver function tests of known or unknown etiology

• Positive Human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C at screening

• History of regular use of tobacco or nicotine-containing products within 6 months of the study

• Unable to abstain from alcohol or caffeine or xanthine-containing products for 24 h prior to the start of dosing

• Unable to refrain from use of prescription or non-prescription drugs and vitamins within 7 days or 5 half-lives (whichever is longer) prior to administration of study

• Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening (Note: This applies to healthy young subjects screened for Cohorts 1-3 only. Healthy elderly subjects for cohort 4 who are social smokers must give up smoking for the period that they will be on the unit)

• positive pre-study drug/alcohol screen

• Unable to refrain from consumption of Seville oranges, grapefruit or grapefruit juice within 7 days prior to the first dose of study medication until the follow-up visit

• Subjects who have taken statins, medicines that are contraindications of statins, know potent inhibitiors or inducers of CYP3A4 in the 4 weeks or 5 half-lives (whichever is longer) prior to screening and are not able to discontinue use throughout participation in the clinical trial

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Intervention

Drug:
• GSK2647544
repeat dose
• drug-drug interaction
drug-drug interaction

Locations

Country	Name	City	State
United Kingdom	GSK Investigational Site	Harrow	Middlesex

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of GSK2647544 as assessed by number of subjects with adverse events (AE)s	Safety and tolerability parameters will include recording of AEs	up to 19 days in each dosing session
Primary	Safety and tolerability of GSK2647544 as assessed by change from Baseline in laboratory values	Safety and tolerability parameters will include laboratory (haematology, clinical chemistry, urinalysis) values at Screening, Day-1, Day 1 to up to Day 15 and Follow-up (7-14 days post-last dose)	up to 15 days in each dosing session
Primary	Safety and tolerability of GSK2647544 as assessed by change from Baseline in ECG readings	Safety and tolerability parameter will include the electrocardiogram (ECG) readings at Screening, Day -1, Day 1 to up to Day 19, and follow-up (7-14 days post-last dose)	up to 19 days in each dosing session
Primary	Safety and tolerability of GSK2647544 as assessed by change from Baseline in Telemetry ECG parameters	Safety and tolerability parameter will include the Telemetry ECG readings from 30 minutes pre-dosing till 24 hours post-dosing	2 days in Cohorts 1, 2 and 4; 3 days in Cohort 4
Primary	Safety and tolerability of GSK2647544 as assessed by change from Baseline in vital signs	Vital signs measurement include systolic and diastolic blood pressure and pulse rate at Screening, Day -1, Day 1 to up to Day 19, and Follow-up (7-14 days post-last dose)	up to 19 days in each dosing session
Primary	Safety and tolerability of GSK2647544 as assessed by Columbia Suicide Severity Rating Scale (C-SSRS)	C-SSRS will be measured at Screening, Day-1, dispersed days during dosing sessions, prior to discharge, and Follow-up (7-14 days post-last dose)	4 days in Cohorts 1 and 2; 8 days in Cohorts 3 and 4
Primary	Peak plasma concentration (Cmax) of GSK2647544	To assess PK profile of GSK2647544, Cmax of GSK2647544 will be measured	up to 17 days in GSK2647544 dosing sessions
Primary	Time of peak plasma concentration (tmax) of GSK2647544	To assess PK profile of GSK2647544, tmax of GSK2647544 will be measured	up to 17 days in GSK2647544 dosing sessions
Primary	Area under the time concentration curve (AUC) of GSK2647544	To assess PK profile of GSK2647544, AUC of GSK2647544 will be measured	up to 17 days in GSK2647544 dosing sessions
Primary	Terminal half-life (t½ ) of GSK2647544	To assess PK profile of GSK2647544, t1/2 of GSK2647544 will be measured	up to 17 days in GSK2647544 dosing sessions
Primary	Time of peak plasma concentration (tmax) of simvastatin	To assess the effect of GSK2647544 on PK profile of simvastatin, tmax of simvastatin will be measured	4 days in Cohorts 1 and 3
Primary	Area under the time concentration curve (AUC) of simvastatin	To assess the effect of GSK2647544 on PK profile of simvastatin, AUC of simvastatin will be measured	4 days in Cohorts 1 and 3
Secondary	Predose plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and postdose Lp-PLA2 activity	Lp-PLA2 activity will be measured at Days 1, 2, 3 and 4 in GSK2647544 single dose sessions; it will be measured at Days 1, 3, 4, 5, 7, 10, 14, 15, 16, 17 and 18 in GSK2647544 repeat dose sessions	up to 18 days in GSK2647544 dosing sessions

External Links

•   Results for study 200592 can be found on the GSK Clinical Study Register.